Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142605 | 0.92 | KDM4E (0.45) | KDM4ENPC1RAB9AKCNH2SETD7 | |
| SCHEMBL3132987 | 0.91 | SETD7 (0.46) | KDM4ENPC1RAB9AKCNH2SETD7 | |
| SCHEMBL490493 | 0.90 | ROCK2 (0.48) | ROCK2KCNH2SETD7ALDH1A1ROCK1 | |
| SCHEMBL490195 | 0.83 | SETD7 (0.51) | KCNH2SETD7ALDH1A1DRD3 | |
| SCHEMBL490196 | 0.83 | SETD7 (0.48) | ROCK2KDM4EKCNH2SETD7ALDH1A1 | |
| SCHEMBL3138213 | 0.80 | MAPK1 (0.46) | ROCK2KDM4EKCNH2SETD7 | |
| SCHEMBL490434 | 0.80 | OPRD1 (0.48) | ROCK2KCNH2SETD7HPGD | |
| SCHEMBL490273 | 0.79 | OPRD1 (0.46) | ROCK2KCNH2DRD3ROCK1 | |
| SCHEMBL3030798 | 0.78 | TP53 (0.60) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL490378 | 0.78 | ROCK2 (0.48) | ROCK2KCNH2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067777-B1 | OXEPIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8222419-B2 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100004456-A1 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2067777-A1 | OXEPIN DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004456-A1 | Oxepin derivative | HRH4, HRH3, HCRTR2 | ROCK2 2930/4885KDM4E 1720/4885NPC1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.